Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;32(4):463-467.
doi: 10.1007/s40292-025-00727-8. Epub 2025 Jul 15.

Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study

Affiliations

Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study

Hesham Sheashaa et al. High Blood Press Cardiovasc Prev. 2025 Jul.

Abstract

Introduction: Lipoprotein(a) [Lp(a)] has been linked to myocardial fibrosis and endothelial dysfunction, proposed mechanisms for diastolic dysfunction (DD). This study assessed the association between elevated Lp(a) (≥ 50 mg/dL) and DD in patients with preserved ejection fraction (EF).

Aim: We analyzed 1492 adults (median age59) with an Lp(a) measurement and echocardiogram (1997-2024).

Methods: Diastolicdysfunction required ≥ 3 abnormal echo parameters, as per recent guidelines. Logisticregression adjusting for potential confounders was performed.

Results: Seventy-sevenpatients (5.1%) had DD. Lp(a) ≥ 50 mg/dL was not associated with DD [adjusted oddsratio (aOR): 0.89, 95% confidence interval (CI): 0.49-1.54]. However, age (aOR:1.03, p = 0.026), hypertension (aOR: 1.83, p = 0.042), diabetes mellitus (aOR: 2.43, p =0.002), and cardiovascular (CV) diseases (aOR: 1.90, p = 0.043) were associated withDD, while statin therapy was associated with reduced risk (aOR: 0.51, p = 0.016).

Conclusions: In the setting of preserved EF, Lp(a) was not associated with DD,emphasizing management of traditional CV risks.

Keywords: Cardiovascular; Cholesterol; Diastolic dysfunction; Lipoprotein.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article. Ethical approval: The study was approved by the Mayo Clinic Institutional Review Board, with informed consent waived due to its retrospective nature.

References

    1. Marcovina SM. Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease. Crit Rev Clin Lab Sci. 2023;60(8):560–72.
    1. Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis. 2022;349:7–16.
    1. Chung CS, Shmuylovich L, Kovacs SJ. What global diastolic function is, what it is not, and how to measure it. Am J Physiol Heart Circ Physiol. 2015;309(9):H1392–406.
    1. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
    1. Chehab O, Abdollahi A, Whelton SP, Wu CO, Ambale-Venkatesh B, Post WS, Bluemke DA, Tsai MY, Lima JAC. Association of Lipoprotein(a) levels with myocardial fibrosis in the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2023;82(24):2280–91.

LinkOut - more resources